Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) said unit Jinzhou Avanc Pharmaceutical's drug registration application of Moxetomidate Hydrochloride Injection was accepted by China's National Medical Products Administration, according to a Friday Hong Kong bourse filing.
The indication under this application is for the induction and maintenance of anesthesia during short surgical procedures.